T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G with the SEC on November 6, 2026, disclosing beneficial ownership of 9,996,124 shares of Xenon Pharmaceuticals Inc. common stock as of October 31, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 9,996,124 shares of Xenon Pharmaceuticals Inc. common stock.
  • Percent of class: The reported holdings represent 10.3% of the class of securities.
  • Sole voting power: The filing disclosed sole voting power over 9,567,544 shares.
  • Sole dispositive power: The filing disclosed sole dispositive power over 9,996,124 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Triggering event date: The date of the event requiring this filing was October 31, 2026.
  • Filer classification: T. Rowe Price Investment Management, Inc. is identified as an investment adviser, organized in Maryland, with a principal business address of 1307 Point Street, Baltimore, MD 21231.

T. Rowe Price Investment Management Discloses 10.3% Position in Xenon Pharmaceuticals

According to the amended Schedule 13G filed on November 6, 2026, T. Rowe Price Investment Management, Inc. reported aggregate beneficial ownership of 9,996,124 shares of common stock in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), representing 10.3% of the class as of October 31, 2026. The filing is designated Amendment No. 1 to a previously filed Schedule 13G. The issuer's principal executive offices are listed as 200 - 3650 Gilmore Way, Burnaby, A1, V5G 4M1.

The filing reports that T. Rowe Price Investment Management, Inc. holds sole voting power over 9,567,544 shares and sole dispositive power over the full 9,996,124 shares. Shared voting power and shared dispositive power are each listed as 0. The filer is classified as an investment adviser (type "IA") incorporated in Maryland.

In the certification included in the filing, T. Rowe Price Investment Management, Inc. stated that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing was signed by Ellen York, Vice President, on November 6, 2026. The filing further states that it "shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."

What Was Disclosed

T. Rowe Price Investment Management, Inc. filed Amendment No. 1 to Schedule 13G disclosing beneficial ownership of 9,996,124 shares, or 10.3%, of Xenon Pharmaceuticals Inc. common stock, with sole voting power over 9,567,544 shares, as of October 31, 2026.